Window of Opportunity Study of DSP-0390 in Gliomas

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

April 17, 2026

Study Completion Date

May 17, 2026

Conditions
Glioma, MalignantGrade II GliomaIDH Mutation
Interventions
DRUG

DSP-0390

DSP-0390 will be administered orally with preferably 200 mL of water, or approximately one-half cup water. The patient will take DSP-0390 after a minimum of a 6-hour fast and will fast for 1 hour after taking the dose.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Sumitomo Pharmaceuticals America

INDUSTRY

lead

Washington University School of Medicine

OTHER